

Medicines and Healthcare Products Regulatory Agency

CERTIFICATE NUMBER: **UK API 4 Insp GMP 4/117769-0019 [H]**

CERTIFICATE OF GMP COMPLIANCE OF A MANUFACTURER^{1, 2}

Part 1

Issued following an inspection in accordance with :

Art. 111(5) of Directive 2001/83/EC as amended

The competent authority of United Kingdom confirms the following:

The manufacturer: **GLAXOSMITHKLINE**

Site address: **COBDEN STREET, MONTROSE, DD10 8EA, United Kingdom**

Is an active substance manufacturer that has been inspected in accordance with Art. 111(1) of Directive 2001/83/EC transposed in the following national legislation:

The Human Medicines Regulations 2012 (SI 2012/1916)

From the knowledge gained during inspection of this manufacturer, the latest of which was conducted on **2019-05-22** , it is considered that it complies with :

- The principles of GMP for active substances³ referred to in Article 47 of Directive 2001/83/EC .

This certificate reflects the status of the manufacturing site at the time of the inspection noted above and should not be relied upon to reflect the compliance status if more than three years have elapsed since the date of that inspection. However, this period of validity may be reduced or extended using regulatory risk management principles by an entry in the Restrictions or Clarifying remarks field. This certificate is valid only when presented with all pages and both Parts 1 and 2. The authenticity of this certificate may be verified in EudraGMDP. If it does not appear, please contact the issuing authority.

¹ The certificate referred to in paragraph 111(5) of Directive 2001/83/EC and 80(5) of Directive 2001/82/EC, shall also be required for imports coming from third countries into a Member State.

² Guidance on the interpretation of this template can be found in the Help menu of EudraGMDP database.

³ These requirements fulfil the GMP recommendations of WHO.

Part 2

Manufacture of active substance. Names of substances subject to inspection :

ZANAMIVIR(en)

SALBUTAMOL SULPHATE(en)

LACIDIPINE(en)

FLUTICASONE PROPIONATE(en)

DUTASTERIDE(en)

CLOBETASONE BUTYRATE(en)

CLOBETASOL PROPIONATE(en)

BETAMETHASONE VALERATE(en)

BETAMETHASONE ALCOHOL(en)

ABACAVIR SULPHATE(en)

3. MANUFACTURING OPERATIONS - ACTIVE SUBSTANCES

Active Substance : ZANAMIVIR

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Drying, Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing 3.6.2 Microbiological testing excluding sterility testing

Active Substance : SALBUTAMOL SULPHATE

3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.3 Salt formation / Purification steps : Sulphate salt formation and crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Drying, Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging

	material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : LACIDIPINE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Drying, Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : FLUTICASONE PROPIONATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Drying, Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : DUTASTERIDE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance

	3.1.3 Salt formation / Purification steps : Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Drying 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : CLOBETASONE BUTYRATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Drying, micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : CLOBETASOL PROPIONATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Drying, Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)

3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : BETAMETHASONE VALERATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.2 Manufacture of crude active substance 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Drying, micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : BETAMETHASONE ALCOHOL	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.3 Salt formation / Purification steps : Crystallisation
3.5	General Finishing Steps
	3.5.1 Physical processing steps : Drying, micronisation 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing
Active Substance : ABACAVIR SULPHATE	
3.1	Manufacture of Active Substance by Chemical Synthesis
	3.1.1 Manufacture of active substance intermediates 3.1.3 Salt formation / Purification steps : Crystallisation and salt formation
3.5	General Finishing Steps
	3.5.1 Physical processing steps :

	Drying, Sieving 3.5.2 Primary Packaging (enclosing / sealing the active substance within a packaging material which is in direct contact with the substance) 3.5.3 Secondary Packaging (placing the sealed primary package within an outer packaging material or container. This also includes any labelling of the material which could be used for identification or traceability (lot numbering) of the active substance)
3.6	Quality Control Testing
	3.6.1 Physical / Chemical testing

Clarifying remarks (for public users)

This certificate is issued based on a desk-based assessment of GMP compliance information provided by the manufacturer. A risk-based site inspection programme remains in force.

2019-05-22

Name and signature of the authorised person of the
Competent Authority of United Kingdom

Confidential
Medicines and Healthcare Products Regulatory Agency
Tel: **Confidential**
Fax: **Confidential**